NIO752 / Novartis - LARVOL DELTA

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Recruiting | N=25 ➔ 36 | Trial completion date: Oct 2025 ➔ Nov 2027 | Trial primary completion date: Oct 2025 ➔ Nov 2027

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APP • Plasma T-Tau

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1 | N=59 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • COMT

NIO-SILK: A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: University College, London

New P1 trial • Alzheimer's Disease • CNS Disorders

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Oct 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APP

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • COMT

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2024 ➔ Nov 2024 | Trial primary completion date: Aug 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • COMT

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Oct 2024 | Initiation date: Sep 2022 ➔ Feb 2023 | Trial primary completion date: Nov 2023 ➔ Oct 2024

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APP

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2024 ➔ Oct 2024 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

DEVELOPMENT OF NIO752, AN INTRATHECALLY ADMINISTERED MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) ANTISENSE OLIGONUCLEOTIDE IN PROGRESSIVE SUPRANUCLEAR PALSY AND ALZHEIMER DISEASE (ADPD 2023) - "The preclinical data s upports clinical development of NIO752 in PSP and AD."

Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • MAPT

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APP

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jan 2025 ➔ May 2024

Trial completion date • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

"Following closely: @Novartis safety, tolerability and pharmacokinetics of #NIO752 in Progressive Supranuclear Palsy to start recruiting ~60 PSP patients early 2021. https://t.co/poUY2rE3Bq" (@KristopheDiaz)

Clinical • PK/PD data • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy (clinicaltrials.gov) - P1; N=64; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy